Key statistics
As of last trade, ProQR Therapeutics NV (0PQ:DUS) traded at 1.66, 57.45% above the 52 week low of 1.05 set on Nov 01, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.66 |
---|---|
High | 1.66 |
Low | 1.66 |
Bid | 1.65 |
Offer | 1.71 |
Previous close | 1.70 |
Average volume | 83.78 |
---|---|
Shares outstanding | 81.68m |
Free float | 66.33m |
P/E (TTM) | -- |
Market cap | 152.74m USD |
EPS (TTM) | -0.2908 USD |
Data delayed at least 15 minutes, as of Oct 09 2024 11:30 BST.
More ▼
Announcements
- ProQR Highlights Upcoming Presentation at 20th Annual Meeting of the Oligonucleotide Therapeutics Society
- ProQR Announces Webcast Presentation at the 2024 Cantor Global Healthcare Conference
- ProQR Announces Second Quarter 2024 Operating and Financial Results
- ProQR Announces Presentation on its Axiomer™ RNA Editing Technology at RNA Editing Summit
- ProQR Announces First Quarter 2024 Operating and Financial Results
- ProQR Announces Preclinical Proof of Concept Data for AX-0810 Axiomer™ RNA Editing Program Targeting NTCP for Cholestatic Diseases
- ProQR Nominates Martin Maier, PhD to Board and Announces Annual Meeting of Shareholders to be Held May 22, 2024
- ProQR Highlights Upcoming Presentations on Axiomer™ RNA Editing at ASGCT 27th Annual Meeting
- ProQR Achieves Successful Defense of New Challenge to its Axiomer™ IP Portfolio
- ProQR Announces Year End 2023 Operating and Financial Results
More ▼